echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Renhe Pharmaceuticals Entecavir Tablets Obtained Drug Registration Certificate

    Renhe Pharmaceuticals Entecavir Tablets Obtained Drug Registration Certificate

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 25, Renhe Pharmaceutical announced that its subsidiary Jiangxi Pharmaceutical has recently received the "Drug Registration Certificate" for Entecavir tablets approved and issued by the State Drug Administration.

    Product entecavir indications: This product is suitable for active viral replication, serum alanine aminotransferase (ALT) continues to rise, or liver histology showed chronic active lesions of adult hepatitis B treatment (including generation of compensation and Patients with liver disease in decompensated stage).
    It is also suitable for the treatment of nucleoside-
    naive children with chronic HBV infection and compensatory liver disease from 2 years old to <18 years old , with evidence of active viral replication and continuous increase in serum ALT levels or with moderate to severe inflammation and/ or fibrosis Histological evidence.

    (ALT) continues to rise or liver histology showed active lesions in the treatment of chronic hepatitis B in adults (including the generation of compensation and patients with decompensated liver disease).
    It is also suitable for the treatment of nucleoside-
    naive children with chronic HBV infection and compensatory liver disease from 2 years old to <18 years old , with evidence of active viral replication and continuous increase in serum ALT levels or with moderate to severe inflammation and/ or fibrosis Histological evidence.

    The acceptance time for Renhe's first submission of the production application for this product is June 12, 2019 (acceptance number: CYHS1900411 ).
    As of the date of this announcement, the accumulated research and development expenses of Entecavir tablets are approximately RMB 8,127,200.

    country).
    As of the date of this announcement, the accumulated research and development expenses of Entecavir tablets are approximately RMB 8,127,200.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.